Mentice AB
STO:MNTC
Mentice AB
Research & Development
Mentice AB
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mentice AB
STO:MNTC
|
Research & Development
-kr6.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RaySearch Laboratories AB (publ)
STO:RAY B
|
Research & Development
-kr270.4m
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
ContextVision AB
OSE:CONTX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Ortivus AB
STO:ORTI B
|
Research & Development
-kr7.7m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Sectra AB
STO:SECT B
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
i
|
iZafe Group AB
STO:IZAFE B
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mentice AB
Glance View
Mentice AB provides software and hardware simulation solutions for endovascular therapies. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2019-06-18. The company provides software and hardware simulation solutions and related services for endovascular therapies. The Company’s solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Company’s solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The firm also covers neurovascular, cardiovascular and peripheral interventions, among others. The company is active globally.
See Also
What is Mentice AB's Research & Development?
Research & Development
-6.8m
SEK
Based on the financial report for Sep 30, 2025, Mentice AB's Research & Development amounts to -6.8m SEK.
What is Mentice AB's Research & Development growth rate?
Research & Development CAGR 1Y
-17%
Over the last year, the Research & Development growth was -17%.
